Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.

Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA ...

HYDERABAD: A study by researchers at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, has identified a ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...